IVAX LLC

CHICAGO, Jan. 10, 2023 /PRNewswire/ -- According to Arizton's latest research report, the fertility supplements market is likely to grow at a CAGR of 8% during 2021-2027. Factors such as growing awareness regarding fertility health, increasing advanced maternal age population (women) in developed and emerging markets, rapidly increasing infertile couples worldwide, and awareness of infertility issues among the global adult population are boosting the fertility supplements market. Continue Reading Fertility Supplements Market Several global and regional players in the market offer a wide range of fertility supplements in natural, synthetic, and blend ingredients. Consumer preference and better clinical outcomes are increasing the demand for fertility supplements. Most vendors are increasingly focused on marketing and extending their product portfolio to gain a competitive edge over other market players. Rapid advances in the fertility supplement industry have significantly impacted the growth of products. Europe is a highly dominating global fertility supplements market region, valued at USD 610.79 million in 2021. Due to the higher awareness level about fertility care and supplements, high expenditure and acceptance of fertility-boosting solutions are expected to fuel the region's market growth. In addition, the increasing infertility prevalence, changing lifestyle, delayed pregnancy, and increasing maternal age are some factors that led to the increasing infertility issues that drive the high demand for fertility care and accelerate the industry growth. In 2021, Italy accounted for 21.70% of the industry share and was the leading country in Europe. The significant industry growth contributing factors addressed in Italy are the significant development and higher acceptance of fertility care services. Fertility Supplements Market Report Scope Click Here to Download the Free Sample Report Rising Focus on Natural Fertility Supplements Natural vitamin E-based fertility products are vital in boosting fertility and are natural antioxidants. It helps the fertilized egg stay attached to the uterine wall. Moreover, Ashwagandha herbs, Vitex, and adaptogens can boost fertility. Maca is a commonly used fertility aid solution. It contains a high level of p-methoxybenzyl isothiocyanate. In some cases, it helps to increase sperm count concentration. Royal jelly is also a natural fertility supplement that increases testosterone. Olive oil and salmon solutions are natural sources of Coenzyme Q10 that are used to boost lagging fertility. It also helps with the energy production of mitochondria to process and recycle energy effectively. Due to proven results in users, the demand for natural fertility supplements is increasing. In addition, many companies are also involved in increasing their natural fertility supplements-based products. New Product Launches In 2022, the leading market player, Ovaterra, launched two prenatal vitamin supplement products, Advanced Prep 35-39 & Advanced Prenatal, designed for pre, during, and post-pregnancy care. In 2022, Wellbeing Nutrition Indian, the fastest-growing plant-based nutrition company, will launch a SLOW nutraceutical product portfolio. In 2022, the Natalist company launched new products such as fertility supplements for every stage of the reproductive journey. The company launched consumer fertility, pregnancy, and essential postpartum products around 100% plastic neutral, including CoQ10 gummies, prenatal gummies, and other fertility and pregnancy test products. Nua fertility is one of the world-class fertility brands focused on innovation and delivery of world-class fertility products. In 2020, the company launched the fertility supplement, NuaBiome, for women. Click Here to Download the Free Sample Report Key Vendors Coast Science Exeltis USA Fairhaven Health LENUS Pharma GesmbH Vitabiotics Ltd. AdvaCare Pharma Bayer Ag Beli CaDi- Cambridge Diagnostic Imaging Carlson Labs DCMG Laboratories Elan Healthcare Eu Natural Fermenta Biotech FullWell Hera (HeraNow) iNova Pharmaceuticals (Pty) Ltd. Laboratorios Fertypharm S.L. Life Extension Nestlé Nature's Craft Nutra Business Nua Fertility Ocean Healthcare Orthomol Ovaterra Pragati Biocare Pvt. Ltd. Premama Puritan's Pride Ritual Renova Nutrition Supplemena Seeking Health TTK Thorne Wellbeing Nutrition Zenith Nutrition Market Segmentation Form Natural Synthetic & Blend Type Capsule Tablet Soft Gel Powder Liquid Gender Women Men Purchase Channels Over-the-counter (OTC) Prescription Geography North America US Canada Europe Germany Italy Spain France UK APAC Japan China South Korea India Australia Latin America Brazil Mexico Argentina Middle East & Africa Turkey Saudi Arabia South Africa UAE Check Out Some of the Top-Selling Related Research Reports: U.S. Assisted Reproductive Technology Market - The U.S. assisted reproductive technology market is expected to cross $4 billion by 2027. Key players with huge infrastructure and R&D support are expanding their footprint in the industry by implementing various marketing strategies to gain traction among end-users and increase their market presence. U.S. Fertility Test Market - U.S. fertility test market is projected to reach USD 201.4 million in 2027. A fertility test is a procedure by which the fertility of males or females can assess, and search the fertile window during a month. Fertility tests are assessed by ovulation test kits, fertility monitors, and sperm testing. The increasing infertility prevalence and rising maternal age directly impact male and female fertility, driving the demand for fertility tests. The U.S. fertility test market is likely to develop due to favorable demographic and social/cultural shifts due to attractive long-term growth. Fertility Test Market - The global fertility test market is expected to reach USD 659.71 million by 2027. The global fertility treatment is presumably to grow healthy due to attractive long-term growth from favorable demographic and social/cultural shifts. Fertility testing is a niche industry with high margins for manufacturers, especially for vendors offering kits, which males and females widely use. U.S. In-Vitro Fertilization (IVF) Market- The U.S. in-vitro fertilization market is expected to reach USD 231.68 million by 2026. The presence of global, regional, and local vendors characterizes the US in-vitro fertilization market. In recent years, the global infertility treatment market has witnessed many strategic initiatives by key vendors, which is expected to intensify market competitiveness in the upcoming years. Infertility treatment is a niche industry with high margins for manufacturers, especially for vendors offering equipment, media, and related consumables, that are widely used during ART procedures. Table of Content 1 RESEARCH METHODOLOGY 2 RESEARCH OBJECTIVES 3 RESEARCH PROCESS 4 SCOPE & COVERAGE 4.1 MARKET DEFINITION 4.1.1 INCLUSIONS 4.1.2 EXCLUSIONS 4.1.3 MARKET ESTIMATION CAVEATS 4.2 BASE YEAR 4.3 SCOPE OF THE STUDY 4.3.1 MARKET SEGMENTATION BY FORM 4.3.2 MARKET SEGMENTATION BY TYPE 4.3.3 MARKET SEGMENTATION BY GENDER 4.3.4 MARKET SEGMENTATION BY PURCHASE CHANNEL 4.3.5 MARKET SEGMENTATION BY GEOGRAPHY 5 REPORT ASSUMPTIONS & CAVEATS 5.1 KEY CAVEATS 5.2 CURRENCY CONVERSION 5.3 MARKET DERIVATION 6 MARKET AT A GLANCE 7 INTRODUCTION 7.1 OVERVIEW 8 PREMIUM INSIGHTS 8.1 OVERVIEW 9 MARKET OPPORTUNITIES & TRENDS 9.1 ADVANCES, RESEARCH, & CREDIBILITY IN FERTILITY SUPPLEMENTS 9.2 INCREASE IN PRODUCT LAUNCHES 9.3 FOCUS ON NATURAL FERTILITY SUPPLEMENTS 10 MARKET GROWTH ENABLERS 10.1 INCREASE IN PREVALENCE OF INFERTILITY RATE 10.2 INCREASE IN GOVERNMENT & PUBLIC INITIATIVES FOR FERTILITY AWARENESS 10.3 TREND OF DELAYED PREGNANCIES 11 MARKET RESTRAINTS 11.1 LACK OF AWARENESS & LOW ACCESS TO FERTILITY TREATMENTS IN EMERGING MARKETS 11.2 SIDE EFFECTS RELATED TO FERTILITY SUPPLEMENTS 11.3 PRESENCE OF ALTERNATIVES TO FERTILITY SUPPLEMENTS 12 MARKET LANDSCAPE 12.1 MARKET OVERVIEW 12.1.1 INSIGHT BY GEOGRAPHY 12.1.2 INSIGHT BY PURCHASE CHANNEL 12.1.3 INSIGHT BY FORM 12.1.4 INSIGHT BY TYPE 12.1.5 INSIGHTS BY GENDER 12.2 MARKET SIZE & FORECAST 12.3 FIVE FORCES ANALYSIS 12.3.1 THREAT OF NEW ENTRANTS 12.3.2 BARGAINING POWER OF SUPPLIERS 12.3.3 BARGAINING POWER OF BUYERS 12.3.4 THREAT OF SUBSTITUTES 12.3.5 COMPETITIVE RIVALRY 13 FORM 13.1 MARKET SNAPSHOT & GROWTH ENGINE 13.2 MARKET OVERVIEW 13.3 NATURAL 13.3.1 MARKET OVERVIEW 13.3.2 MARKET SIZE & FORECAST 13.3.3 MARKET BY GEOGRAPHY 13.4 SYNTHETIC & BLEND 13.4.1 MARKET OVERVIEW 13.4.2 MARKET SIZE & FORECAST 13.4.3 MARKET BY GEOGRAPHY 14 TYPE 14.1 MARKET SNAPSHOT & GROWTH ENGINE 14.2 MARKET OVERVIEW 14.3 CAPSULE 14.3.1 MARKET OVERVIEW 14.3.2 MARKET SIZE & FORECAST 14.3.3 MARKET BY GEOGRAPHY 14.4 TABLET 14.4.1 MARKET OVERVIEW 14.4.2 MARKET SIZE & FORECAST 14.4.3 MARKET BY GEOGRAPHY 14.5 SOFT GEL 14.5.1 MARKET OVERVIEW 14.5.2 MARKET SIZE & FORECAST 14.5.3 MARKET BY GEOGRAPHY 14.6 POWDER 14.6.1 MARKET OVERVIEW 14.6.2 MARKET SIZE & FORECAST 14.6.3 MARKET BY GEOGRAPHY 14.7 LIQUID 14.7.1 MARKET OVERVIEW 14.7.2 MARKET SIZE & FORECAST 14.7.3 MARKET BY GEOGRAPHY 15 GENDER 15.1 MARKET SNAPSHOT & GROWTH ENGINE 15.2 MARKET OVERVIEW 15.3 WOMEN 15.3.1 MARKET OVERVIEW 15.3.2 MARKET SIZE & FORECAST 15.3.3 MARKET BY GEOGRAPHY 15.4 MEN 15.4.1 MARKET OVERVIEW 15.4.2 MARKET SIZE & FORECAST 15.4.3 MARKET BY GEOGRAPHY 16 PURCHASE CHANNEL 16.1 MARKET SNAPSHOT & GROWTH ENGINE 16.2 MARKET OVERVIEW 16.3 OVER-THE-COUNTER (OTC) 16.3.1 MARKET OVERVIEW 16.3.2 MARKET SIZE & FORECAST 16.3.3 MARKET BY GEOGRAPHY 16.4 PRESCRIPTION 16.4.1 MARKET OVERVIEW 16.4.2 MARKET SIZE & FORECAST 16.4.3 MARKET BY GEOGRAPHY 17 GEOGRAPHY 17.1 MARKET SNAPSHOT & GROWTH ENGINE 17.2 GEOGRAPHIC OVERVIEW 18 EUROPE 18.1 MARKET OVERVIEW 18.2 MARKET SIZE & FORECAST 18.3 FORM 18.3.1 MARKET SIZE & FORECAST 18.4 TYPE 18.4.1 MARKET SIZE & FORECAST 18.5 GENDER 18.5.1 MARKET SIZE & FORECAST 18.6 PURCHASE CHANNEL 18.6.1 MARKET SIZE & FORECAST 18.7 KEY COUNTRIES 18.7.1 ITALY: MARKET SIZE & FORECAST 18.7.2 SPAIN: MARKET SIZE & FORECAST 18.7.3 GERMANY: MARKET SIZE & FORECAST 18.7.4 UK: MARKET SIZE & FORECAST 18.7.5 FRANCE: MARKET SIZE & FORECAST 19 NORTH AMERICA 19.1 MARKET OVERVIEW 19.2 MARKET SIZE & FORECAST 19.3 FORM 19.3.1 MARKET SIZE & FORECAST 19.4 TYPE 19.4.1 MARKET SIZE & FORECAST 19.5 GENDER 19.5.1 MARKET SIZE & FORECAST 19.6 PURCHASE CHANNEL 19.6.1 MARKET SIZE & FORECAST 19.7 KEY COUNTRIES 19.7.1 US: MARKET SIZE & FORECAST 19.7.2 CANADA: MARKET SIZE & FORECAST 20 APAC 20.1 MARKET OVERVIEW 20.2 MARKET SIZE & FORECAST 20.3 FORM 20.3.1 MARKET SIZE & FORECAST 20.4 TYPE 20.4.1 MARKET SIZE & FORECAST 20.5 GENDER 20.5.1 MARKET SIZE & FORECAST 20.6 PURCHASE CHANNEL 20.6.1 MARKET SIZE & FORECAST 20.7 KEY COUNTRIES 20.7.1 JAPAN: MARKET SIZE & FORECAST 20.7.2 CHINA: MARKET SIZE & FORECAST 20.7.3 INDIA: MARKET SIZE & FORECAST 20.7.4 SOUTH KOREA: MARKET SIZE & FORECAST 20.7.5 AUSTRALIA: MARKET SIZE & FORECAST 21 LATIN AMERICA 21.1 MARKET OVERVIEW 21.2 MARKET SIZE & FORECAST 21.3 FORM 21.3.1 MARKET SIZE & FORECAST 21.4 TYPE 21.4.1 MARKET SIZE & FORECAST 21.5 GENDER 21.5.1 MARKET SIZE & FORECAST 21.6 PURCHASE CHANNEL 21.6.1 MARKET SIZE & FORECAST 21.7 KEY COUNTRIES 21.7.1 BRAZIL: MARKET SIZE & FORECAST 21.7.2 MEXICO: MARKET SIZE & FORECAST 21.7.3 ARGENTINA: MARKET SIZE & FORECAST 22 MIDDLE EAST & AFRICA 22.1 MARKET OVERVIEW 22.2 MARKET SIZE & FORECAST 22.3 FORM 22.3.1 MARKET SIZE & FORECAST 22.4 TYPE 22.4.1 MARKET SIZE & FORECAST 22.5 GENDER 22.5.1 MARKET SIZE & FORECAST 22.6 PURCHASE CHANNEL 22.6.1 MARKET SIZE & FORECAST 22.7 KEY COUNTRIES 22.7.1 TURKEY: MARKET SIZE & FORECAST 22.7.2 SAUDI ARABIA: MARKET SIZE & FORECAST 22.7.3 SOUTH AFRICA: MARKET SIZE & FORECAST 22.7.4 UAE: MARKET SIZE & FORECAST 23 COMPETITIVE LANDSCAPE 23.1 COMPETITION OVERVIEW 23.2 MARKET SHARE ANALYSIS 23.2.1 COAST SCIENCE 23.2.2 EXELTIS USA 23.2.3 FAIRHAVEN HEALTH 23.2.4 LENUS PHARMA GESMBH 23.2.5 VITABIOTICS 24 KEY COMPANY PROFILES 24.1 COAST SCIENCE 24.1.1 BUSINESS OVERVIEW 24.1.2 PRODUCT OFFERINGS 24.1.3 KEY STRATEGIES 24.1.4 KEY STRENGTHS 24.1.5 KEY OPPORTUNITIES 24.2 EXELTIS USA 24.3 FAIRHAVEN HEALTH 24.4 LENUS PHARMA GESMBH 24.5 VITABIOTICS 25 OTHER PROMINENT VENDORS 25.1 ADVACARE PHARMA 25.1.1 BUSINESS OVERVIEW 25.1.2 PRODUCT OFFERINGS 25.2 BAYER AG 25.3 BELI 25.4 CADI - CAMBRIDGE DIAGNOSTIC IMAGING 25.5 CARLSON LABS 25.6 DCMG LABORATORIES 25.7 ELAN HEALTHCARE 25.8 EU NATURAL 25.9 FERMENTA BIOTECH 25.10 FULLWELL 25.11 HERA (HERANOW) 25.12 INOVA PHARMACEUTICALS (PTY) LTD. 25.13 LABORATORIOS FERTYPHARM S.L. 25.14 LIFE EXTENSION 25.15 NESTLÉ 25.16 NATURE'S CRAFT 25.17 NUTRA BUSINESS 25.18 NUA FERTILITY 25.19 OCEAN HEALTHCARE 25.20 ORTHOMOL 25.21 OVATERRA 25.22 PRAGATI BIOCARE PVT. LTD. 25.23 PREMAMA 25.24 PURITAN'S PRIDE 25.25 RITUAL 25.26 RENOVA NUTRITION 25.27 SUPPLEMENA 25.28 SEEKING HEALTH 25.29 TTK 25.30 THORNE 25.31 WELLBEING NUTRITION 25.32 ZENITH NUTRITION 26 REPORT SUMMARY 26.1 KEY TAKEAWAYS 26.2 STRATEGIC RECOMMENDATIONS 27 QUANTITATIVE SUMMARY 27.1 MARKET BY GEOGRAPHY 27.2 MARKET BY FORM 27.3 MARKET BY TYPE 27.4 MARKET BY GENDER 27.5 MARKET BY PURCHASE CHANNEL 27.6 FORM: MARKET BY GEOGRAPHY 27.6.1 NATURAL: MARKET BY GEOGRAPHY 27.6.2 SYNTHETIC & BLEND: MARKET BY GEOGRAPHY 27.7 TYPE: MARKET BY GEOGRAPHY 27.7.1 CAPSULE: MARKET BY GEOGRAPHY 27.7.2 TABLET: MARKET BY GEOGRAPHY 27.7.3 SOFT GEL: MARKET BY GEOGRAPHY 27.7.4 POWDER: MARKET BY GEOGRAPHY 27.7.5 LIQUID: MARKET BY GEOGRAPHY 27.8 GENDER: MARKET BY GEOGRAPHY 27.8.1 WOMEN: MARKET BY GEOGRAPHY 27.8.2 MEN: MARKET BY GEOGRAPHY 27.9 PURCHASE CHANNEL: MARKET BY GEOGRAPHY 27.9.1 OTC: MARKET BY GEOGRAPHY 27.9.2 PRESCRIPTION: MARKET BY GEOGRAPHY 28 APPENDIX 28.1 ABBREVIATIONS About Us :  Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services. We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts. Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.  Click Here to Contact Us  Call: +1-312-235-2040            +1 302 469 0707  Mail: [email protected] Photo: Logo: SOURCE Arizton Advisory & Intelligence

PROVIDENCE, R.I., Oct. 31, 2022 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is pleased to announce participation in a new project with Intravacc, funded by CEPI (Coalition for Epidemic Preparedness Innovations), to develop universal vaccines for betacoronaviruses, including SARS-CoV-2. EpiVax will be carrying out the vaccine epitope selection portion of the collaboration using their comprehensive in silico vaccine design toolkit " iVAX". Continue Reading This program is funded under CEPI's 2021 call for proposals to accelerate the development of broadly protective coronavirus vaccines, which will provide up to US$200 million for such projects. Intravacc was awarded $4.8 million to advance their subunit vaccine candidate "Avacc 101", which is designed for intranasal delivery to provide protective immunity for multiple betacoronaviruses including SARS-CoV-1, SARS-CoV-2, and MERS-CoV. Avacc 101 uses Intravacc's Outer Membrane Vesicle (OMV) technology to deliver vaccine payloads for an effective immune response. EpiVax joins forces with Intravacc and CEPI to accelerate development of a universal betacoronavirus vaccine. Tweet this As a subgrantee on the project, EpiVax will identify cross-reactive beta-coronavirus T cell epitopes for broad coverage of COVID-19, MERS and SARS Class 1 and Class 2 HLA-restricted epitopes, using the iVAX in silico vaccine design toolkit. In addition to vaccine epitope selection, EpiVax will also develop multiple designs, and will validate these in silico constructs in vivo with HLA-transgenic mice. According to EpiVax CEO/CSO Dr. Annie De Groot, "We sincerely appreciate the opportunity to apply our advanced vaccine design tools to a problem of global significance.". About EpiVax: EpiVax is a biotechnology company with expertise in T cell epitope prediction, immune modulation, and rapid vaccine design. EpiVax's immunogenicity screening toolkits for therapeutics and vaccines, ISPRI and iVAX, are employed in advancing the research of a global roster of companies. For more information, visit . About Intravacc: Intravacc is a leading global contract development and manufacturing organization (CDMO) of innovative vaccines against infectious diseases. Intravacc has transferred its technology related to polio vaccines, measles vaccines, DPT vaccines, Hib vaccines and influenza vaccines around the world. Intravacc offers a wide range of expertise to develop vaccine from concept to Phase I/II clinical studies for academic, industry and philanthropic partners. For more information, visit . Press Contact: Katie Porter, Associate Director, Business Development & Marketing EpiVax [email protected] Source: EpiVax, Inc. SOURCE EpiVax Inc.

Lia Shaked Welcome to this week's Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please submit the good news—or the bad—from your shop, and we will feature it here at the end of each week. Walgreens Boots Alliance John Driscoll was picked by Walgreens Boots Alliance to lead U.S. healthcare, including Walgreens Health, as executive vice president and president. Driscoll will report directly to Roz Brewer, CEO of WBA. Driscoll joined the company after WBA accelerated its plans to gain full ownership over CareCentrix. Driscoll has held the role of chief executive officer of the home care provider for nearly a decade. His tenure in healthcare spans 25 years and includes companies such as Castlight Health where he served as president, group president at Medco and founder of Surescripts ePrescribing Network. WBA completed its purchase of CareCentrix as it continues to expand into primary care, post-acute care and home care. The deal to purchase the remaining 45% of the company for roughly $392 million is slated to be completed in March 2023. As Driscoll moves into his new role later this month, CareCentrix Chief Financial Officer Steve Horowitz will assume the role of CareCentrix chief executive officer. Hims & Hers Health Brian O’Shaughnessy has be tapped as Hims & Hers Health’s first chief communications officer, and Josh Krueger has been named vice president of fulfillment operations. O’Shaughnessy is a Silicon Valley communications veteran with experience at Google and Skype. At Google, he led consumer product communications across a handful of products and services, including the first Android-powered device, the Chrome browser and the internationalization and monetization of YouTube. Kruger brings over a decade of experience in fulfillment leadership roles at Walmart and Amazon. During his seven-year tenure at Amazon, Krueger helped open four one-million-plus square foot fulfillment centers and launch and operate Amazon’s first fully scaled robotics fulfillment center. The two are the most recent leadership appointments with others including Chief Financial Officer Yemi Okupe, Chief Growth Officer Mike Chi and SVP of Human Resources Amee Parekh. AmeriHealth Caritas AmeriHealth Caritas announced the appointment of Ash Hanson as executive vice president and chief human resources officer. In her new roles, Hanson will oversee associate relations, learning, development, benefits and recruiting for the company’s 8,000 associates. She brings 20 years of experience at Aramark where she most recently held the position of chief diversity and sustainability officer. “AmeriHealth Caritas is committed to being a place where all associates can learn, grow and work together to make a positive impact in the communities we serve,” said AmeriHealth Caritas CEO Paul Tufano. “Central to that mission is ensuring our workforce represents the diversity of voices and experiences essential to innovative solutions for those most in need. Ash’s demonstrated leadership in creating impactful HR solutions will strengthen our workforce and advance our mission of building healthy communities.”  Hanson succeeds Carol Pandza, who will retire at the end of the year. MetroPlusHealth Erin Drinkwater was named MetroPlusHealth’s first chief of government relations and strategic partnerships. In the new position, Drinkwater will develop relationships with elected officials to advance MetroPlusHealth’s mission of equity advancement in New York City’s underserved communities through local, state and federal legislation. Drinkwater joins NYC’s health plan after 20 years in government and nonprofit work including legislative advocacy and policy analysis. She worked as deputy commissioner of intergovernmental and legislative affairs at the NYC Department of Social Services. In this position, she functioned as the agency's intergovernmental representative to various government levels. “I am thrilled to join the dynamic team at MetroPlusHealth to advance the goal of providing low to no cost, high-quality health care,” Drinkwater said. “Throughout my career, I have been focused on making government programs and services more accessible. I look forward to bringing my decades of experience serving New Yorkers in need to my new role.” > CVS Health welcomed Gary Nuzzi as vice president of public and government affairs.  > CirrusMD, the on-demand virtual care provider, tapped Jamie Hall as president and chief executive officer and also elected him to the company's board of directors. > NorthBay Health Chief Financial Officer Michele Bouit will step down from the role at the health system Nov. 18. > Zing Health, a Medicare Advantage plan focused on the underserved, has appointed Ben Miller as its new chief growth officer.  > Parkview Health announced that Mike Packnett is retiring as chief executive officer of the Fort Wayne, Indiana-based health system. > Columbia Memorial Health announced that Jay Cahalan is set to retire at the end of 2022. Dorothy Urschel will take his place as president and chief executive officer. > Phoenix-based Banner Health named Michael Kupferman, M.D., its senior vice president of physician enterprise. > Wiggin and Dana LLP announced that Jolie Apicella, former assistant U.S. attorney and healthcare fraud chief in the U.S. Attorney’s Office for the Eastern District of New York, is joining the firm’s New York office as a partner in its litigation, healthcare and white collar departments. > Florida-based Memorial Healthcare System picked Monica Puga to fill the role of chief nursing executive. > MyndVR hired Robin Viles as the new senior vice president of clinical operations of the virtual reality care company. > Wisp, a digital health company, appointed Laura Purdy, M.D., to be their chief medical officer. > Mount Carmel Health System chose Andy Priday as chief financial officer of the Ohio-based health system. > Bicycle Health, a virtual opioid use disorder treatment platform, announced the hiring of two new executives on its leadership team: Chief Technology Officer Chris Norris and Chief Commercial Officer Justin Guadagno.  > TeleTracking, a healthcare operations company, unveiled Michelle Skinner as chief clinical executive.